Y
Yoshifumi Shimada
Researcher at Niigata University
Publications - 131
Citations - 1242
Yoshifumi Shimada is an academic researcher from Niigata University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 17, co-authored 91 publications receiving 823 citations.
Papers
More filters
Journal ArticleDOI
Next generation sequencing-based gene panel tests for the management of solid tumors.
Masayuki Nagahashi,Yoshifumi Shimada,Hiroshi Ichikawa,Hitoshi Kameyama,Kazuaki Takabe,Kazuaki Takabe,Kazuaki Takabe,Shujiro Okuda,Toshifumi Wakai +8 more
TL;DR: The concept of precision cancer medicine using target sequences in gene panel tests as well as the importance of the control of sample quality in routine NGS‐based genomic testing are described.
Journal ArticleDOI
Site-specific tumor grading system in colorectal cancer: multicenter pathologic review of the value of quantifying poorly differentiated clusters.
Hideki Ueno,Kazuo Hase,Yojiro Hashiguchi,Hideyuki Shimazaki,Masafumi Tanaka,Ohki Miyake,Tadahiko Masaki,Yoshifumi Shimada,Yusuke Kinugasa,Yoshiyuki Mori,Mitsuo Kishimoto,Shingo Kameoka,Yu Sato,Keiji Matsuda,Koichi Nakadoi,Eiji Shinto,Takahiro Nakamura,Kenichi Sugihara +17 more
TL;DR: Multivariate analysis showed that GradePDC exerted an influence on prognostic outcome independently of TNM staging and has a robust prognostic power and promises to be of sufficient clinical value to merit implementation as a site-specific grading system in CRC.
Journal ArticleDOI
Genomic landscape of colorectal cancer in Japan: clinical implications of comprehensive genomic sequencing for precision medicine
Masayuki Nagahashi,Toshifumi Wakai,Yoshifumi Shimada,Hiroshi Ichikawa,Hitoshi Kameyama,Takashi Kobayashi,Jun Sakata,Ryoma Yagi,Nobuaki Sato,Yuko Kitagawa,Hiroyuki Uetake,Kazuhiro Yoshida,Eiji Oki,Shin-ei Kudo,Hiroshi Izutsu,Keisuke Kodama,Mitsutaka Nakada,Julie Y. Tse,Meaghan Russell,Joerg Heyer,Winslow Powers,Ruobai Sun,Jennifer E. Ring,Kazuaki Takabe,Kazuaki Takabe,Alexei Protopopov,Yiwei Ling,Shujiro Okuda,Stephen Lyle +28 more
TL;DR: Use of a panel of 415 genes can reliably identify all of the critical mutations in CRC patients and this information of CGS can be used to determine the most optimal treatment for patients of all ethnicities.
Journal ArticleDOI
Actionable gene-based classification toward precision medicine in gastric cancer
Hiroshi Ichikawa,Masayuki Nagahashi,Yoshifumi Shimada,Takaaki Hanyu,Takashi Ishikawa,Hitoshi Kameyama,Takashi Kobayashi,Jun Sakata,Hiroshi Yabusaki,Satoru Nakagawa,Nobuaki Sato,Yuki Hirata,Yuko Kitagawa,Toshiyuki Tanahashi,Kazuhiro Yoshida,Ryota Nakanishi,Eiji Oki,Dana Vuzman,Dana Vuzman,Stephen Lyle,Kazuaki Takabe,Kazuaki Takabe,Yiwei Ling,Shujiro Okuda,Kohei Akazawa,Toshifumi Wakai +25 more
TL;DR: The clinical utility of this actionable gene-based classification was demonstrated by a case of unresectable GC with a remarkable response to anti-HER2 therapy in the ERBB2 cluster, and a framework for further studies for realizing precision medicine in GC.
Journal ArticleDOI
Poorly Differentiated Clusters Predict Colon Cancer Recurrence: An In-Depth Comparative Analysis of Invasive-Front Prognostic Markers.
Tsuyoshi Konishi,Yoshifumi Shimada,Lik Hang Lee,Marcela S. Cavalcanti,Meier Hsu,J. Joshua Smith,Garrett M. Nash,Larissa K. Temple,Jose G. Guillem,Philip B. Paty,Julio Garcia-Aguilar,Efsevia Vakiani,Mithat Gonen,Jinru Shia,Martin R. Weiser +14 more
TL;DR: It is indicated that PDCs are the best invasive-front histologic marker in terms of prognostic accuracy and interobserver agreement and may replace WHO grade as a prognostic indicator.